The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes

NCT ID: NCT01508338

Last Updated: 2017-08-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to

* determine the effects of 12 weeks of HMB free acid gel, ATP, and HMB free acid gel plus ATP supplementation in trained individuals during a periodized training program on skeletal muscle hypertrophy, body composition, strength, force, velocity, and peak power during loaded and unloaded vertical jumps.

Additionally, the study will determine if either supplementation protocol prevents the typical decay seen in performance following an overreaching cycle performed in the 9th and 10th weeks of the study.

Finally, the study will elucidate the mechanisms of action of supplementation on protein breakdown by analyzing serum indices of muscle damage (CK, LDH) and anabolic status (Testosterone:Cortisol ratio) as well as a urinary indicator of protein breakdown (3-methylhistidine).

We hypothesize that under these conditions that the supplementation protocols will augment skeletal muscle hypertrophy, strength, and power and that HMB will blunt increases in serum indices of muscle damage, and urinary indices of protein breakdown.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In a randomized and double blind study the subjects will consume either placebo supplements, HMB supplement, ATP supplement, or HMB plus ATP supplements for 12 weeks. While consuming the supplements the subjects will undergo an extensive resistance training program designed to train all major muscle groups. An additional overreaching training cycle during weeks 9 and 10 which will involve a high-volume, hypertrophy style training program.

Subject testing will consist of the following:

* Strength and power at weeks 0, 1, 4, 8, 9, 10, and 12
* Range of motion and muscle soreness at weeks 0, 1, 8, 9, and 10
* Body composition and muscle assessments at weeks 0, 1, 4, 8, 9, 10, and 12
* Body fat assessments at weeks 0, 4, 8, and 12
* Blood biochemical measurements at weeks 0, 1, 4, 8, 9, 10, and 12
* Urinary analysis for protein breakdown (3-methylhistidine) at 0, 1, 8, 9, and 10 weeks

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Experienced Weight Training Males

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.

HMB

Group Type EXPERIMENTAL

HMB

Intervention Type DIETARY_SUPPLEMENT

A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.

ATP and HMB

Group Type EXPERIMENTAL

Peak ATP and HMB

Intervention Type DIETARY_SUPPLEMENT

One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.

ATP

Group Type EXPERIMENTAL

ATP

Intervention Type DIETARY_SUPPLEMENT

One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.

Intervention Type DIETARY_SUPPLEMENT

HMB

A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.

Intervention Type DIETARY_SUPPLEMENT

Peak ATP and HMB

One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.

Intervention Type DIETARY_SUPPLEMENT

ATP

One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have 3 years minimum of free weight training experience
* Can squat a minimum of 1.5 times their bodyweight
* Can bench press a minimum equal to their bodyweight
* Can deadlift a minimum of 1.5 times their bodyweight
* Are free of musculoskeletal injuries
* Have not taken creatine or HMB supplements for 6 weeks
* Are not taking amino acid supplements
* Are not using anabolic or catabolic hormones
* Are not taking medications that may interfere with study measurements
* Are not users of tobacco products

Exclusion Criteria

* Do not have 3 years minimum of free weight training experience
* Can not squat a minimum of 1.5 times their bodyweight
* Can not bench press a minimum equal to their bodyweight
* Can not deadlift a minimum of 1.5 times their bodyweight
* Are not free of musculoskeletal injuries
* Have not taken creatine or HMB supplements in the past 6 weeks
* Are currently taking amino acid supplements
* Are using anabolic or catabolic hormones
* Are taking medications that may interfere with study measurements
* Use of tobacco products
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Tampa

OTHER

Sponsor Role collaborator

Metabolic Technologies Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John A Rathmacher, PhD

Role: STUDY_DIRECTOR

Metabolic Technologies Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Tampa

Tampa, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Wilson JM, Joy JM, Lowery RP, Roberts MD, Lockwood CM, Manninen AH, Fuller JC, De Souza EO, Baier SM, Wilson SM, Rathmacher JA. Effects of oral adenosine-5'-triphosphate supplementation on athletic performance, skeletal muscle hypertrophy and recovery in resistance-trained men. Nutr Metab (Lond). 2013 Sep 22;10(1):57. doi: 10.1186/1743-7075-10-57.

Reference Type DERIVED
PMID: 24330670 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MTI2012-CS01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.